ION582 + Placebo
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Angelman Syndrome
Conditions
Angelman Syndrome
Trial Timeline
Jun 10, 2025 → Apr 1, 2030
NCT ID
NCT06914609About ION582 + Placebo
ION582 + Placebo is a phase 3 stage product being developed by Ionis Pharmaceuticals for Angelman Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06914609. Target conditions include Angelman Syndrome.
What happened to similar drugs?
0 of 2 similar drugs in Angelman Syndrome were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
17
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06914609 | Phase 3 | Recruiting |
Competing Products
9 competing products in Angelman Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| RO7248824 | Roche | Phase 1 | 29 |
| RO7248824 | Roche | Phase 1 | 29 |
| Alogabat | Roche | Phase 2 | 35 |
| ION582 | Ionis Pharmaceuticals | Phase 1/2 | 36 |
| GTX-102 | Ultragenyx Pharmaceutical | Phase 3 | 38 |
| GTX-102 | Ultragenyx Pharmaceutical | Phase 3 | 41 |
| GTX-102 | Ultragenyx Pharmaceutical | Phase 2 | 36 |
| GTX-102 | Ultragenyx Pharmaceutical | Phase 1/2 | 26 |
| NNZ-2591 | Neuren Pharmaceuticals | Phase 2 | 29 |